John A. Thompson
Seattle Cancer Care Alliance · 162 works · 17,880 citations · h-index 54
Top works
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome
- Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma
- Guidelines of care for the management of primary cutaneous melanoma
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus
- Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
- Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
- Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
- Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma
- Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
- Age-Specific Incidence of Melanoma in the United States